Literature DB >> 27660682

The Added Value of Assessing Ligand-Receptor Binding Kinetics in Drug Discovery.

Dong Guo1, Laura H Heitman2, Adriaan P IJzerman2.   

Abstract

In the past decade drug research community has started to appreciate the indispensable role of ligand-receptor binding kinetics (BK) in drug discovery. Next to the classical equilibrium-based drug evaluation process with affinity and potency values as outcomes, kinetic investigation of the ligand-receptor interaction can aid compound triage in the hit-to-lead campaign and provide additional information to understand the molecular mechanism of drug action. Translational models incorporating BK are emerging as well, which represent powerful tools for the prediction of in vivo effects. In this viewpoint we will summarize some recent findings and discuss and emphasize the added value of ligand-receptor binding kinetics in drug research.

Year:  2016        PMID: 27660682      PMCID: PMC5018870          DOI: 10.1021/acsmedchemlett.6b00273

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  13 in total

Review 1.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  The Role of Target Binding Kinetics in Drug Discovery.

Authors:  Dong Guo; Laura H Heitman; Adriaan P IJzerman
Journal:  ChemMedChem       Date:  2015-08-25       Impact factor: 3.466

Review 3.  Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.

Authors:  Wilhelmus E A de Witte; Yin Cheong Wong; Indira Nederpelt; Laura H Heitman; Meindert Danhof; Piet H van der Graaf; Ron A H J Gilissen; Elizabeth C M de Lange
Journal:  Expert Opin Drug Discov       Date:  2015-10-20       Impact factor: 6.098

Review 4.  Drug-target residence time--a case for G protein-coupled receptors.

Authors:  Dong Guo; Julia M Hillger; Adriaan P IJzerman; Laura H Heitman
Journal:  Med Res Rev       Date:  2014-02-18       Impact factor: 12.944

Review 5.  Drug-target residence time and its implications for lead optimization.

Authors:  Robert A Copeland; David L Pompliano; Thomas D Meek
Journal:  Nat Rev Drug Discov       Date:  2006-08-04       Impact factor: 84.694

Review 6.  Pharmacokinetics and the drug-target residence time concept.

Authors:  Göran Dahl; Tomas Akerud
Journal:  Drug Discov Today       Date:  2013-03-14       Impact factor: 7.851

7.  Translating slow-binding inhibition kinetics into cellular and in vivo effects.

Authors:  Grant K Walkup; Zhiping You; Philip L Ross; Eleanor K H Allen; Fereidoon Daryaee; Michael R Hale; John O'Donnell; David E Ehmann; Virna J A Schuck; Ed T Buurman; Allison L Choy; Laurel Hajec; Kerry Murphy-Benenato; Valerie Marone; Sara A Patey; Lena A Grosser; Michele Johnstone; Stephen G Walker; Peter J Tonge; Stewart L Fisher
Journal:  Nat Chem Biol       Date:  2015-04-20       Impact factor: 15.040

8.  Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9.

Authors:  Pelin Ayaz; Dorothee Andres; Dennis A Kwiatkowski; Carl-Christian Kolbe; Philip Lienau; Gerhard Siemeister; Ulrich Lücking; Christian M Stegmann
Journal:  ACS Chem Biol       Date:  2016-04-19       Impact factor: 5.100

9.  Equilibrium and kinetic selectivity profiling on the human adenosine receptors.

Authors:  Dong Guo; Gabrielle S Dijksteel; Tirsa van Duijl; Maxime Heezen; Laura H Heitman; Adriaan P IJzerman
Journal:  Biochem Pharmacol       Date:  2016-02-27       Impact factor: 5.858

10.  A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics.

Authors:  X Zhou; Drh Huntjens; Rahj Gilissen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-10-09
View more
  9 in total

1.  Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.

Authors:  Angela Arsova; Thor C Møller; Line Vedel; Jakob Lerche Hansen; Simon R Foster; Karen J Gregory; Hans Bräuner-Osborne
Journal:  Mol Pharmacol       Date:  2020-05-01       Impact factor: 4.436

2.  Rapid Quantification of Protein-Ligand Binding via 19F NMR Lineshape Analysis.

Authors:  Samantha S Stadmiller; Jhoan S Aguilar; Christopher A Waudby; Gary J Pielak
Journal:  Biophys J       Date:  2020-04-15       Impact factor: 4.033

Review 3.  Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics.

Authors:  Fereidoon Daryaee; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2019-04-28       Impact factor: 8.822

4.  Systematic Dissociation Pathway Searches Guided by Principal Component Modes.

Authors:  Zhiye Tang; Chia-En A Chang
Journal:  J Chem Theory Comput       Date:  2017-05-01       Impact factor: 6.006

5.  Drug-Target Kinetics in Drug Discovery.

Authors:  Peter J Tonge
Journal:  ACS Chem Neurosci       Date:  2017-07-14       Impact factor: 4.418

6.  Potent Prearranged Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor.

Authors:  Ben J Jones; Rosario Scopelliti; Alejandra Tomas; Stephen R Bloom; David J Hodson; Johannes Broichhagen
Journal:  ChemistryOpen       Date:  2017-06-05       Impact factor: 2.911

7.  Mapping the Ligand Binding Landscape.

Authors:  Alex Dickson
Journal:  Biophys J       Date:  2018-09-29       Impact factor: 4.033

8.  Two for the Price of One: Heterobivalent Ligand Design Targeting Two Binding Sites on Voltage-Gated Sodium Channels Slows Ligand Dissociation and Enhances Potency.

Authors:  Alicia Peschel; Fernanda C Cardoso; Andrew A Walker; Thomas Durek; M Rhia L Stone; Nayara Braga Emidio; Philip E Dawson; Markus Muttenthaler; Glenn F King
Journal:  J Med Chem       Date:  2020-10-20       Impact factor: 7.446

Review 9.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.